ReviewFrontiers in immunology2026
Immune-mediated skin diseases and erectile dysfunction: mechanisms and multidisciplinary management.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global prevalence of erectile dysfunction (ED) continues to rise, which has become an important issue affecting the physical and mental health of men. Existing evidence suggests that ED is closely related to various immune-mediated skin diseases. This review elaborates on the epidemiological characteristics, potential mechanisms, and clinical management strategies of ED associated with immune-mediated skin diseases. It discusses the future research directions and challenges in this field. Epidemiological studies consistently show that the prevalence of ED in such patients is higher than that in the general population, indicating that immune-mediated skin diseases may significantly increase the risk of ED. Its pathogenesis is complex and diverse, involving the interaction of multiple pathways. In terms of clinical management, a multidisciplinary collaborative model is advocated, with the active control of the inflammatory activity of the primary skin disease as the cornerstone of treatment. The treatment of ED should be individualized, combined with psychological intervention and lifestyle optimization, to comprehensively improve the treatment effect. Future research should further explore its molecular mechanisms and conduct large-sample, prospective clinical trials to optimize treatment strategies and ultimately enhance patients' sexual health and overall quality of life (QoL).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.